NVD_OUT_1 [2025-04-16 13:59:33 -0400] 2858 Bytes | 752 tokens | Cum: 752 tkns (9.40% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and GraniteShares ETF Trust (NVD) hit my radar screen, up to 32.0790 from a prev close of 27.2000 Do you think its got more juice or is it lacking potential? It's 1:59:32 PM on Wed Apr 16, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: GraniteShares ETF Trust (NVD)
IPO: 2023-08-22 (1 Year Ago)
Shares Outstanding: 2,170,000
Exchange: XNAS

Here’s a list of headlines for GraniteShares ETF Trust:

Mar-26-25 02:18PM - Inverse Leveraging Tesla's Decline With TSLZ: A Bear Vehicle Worth Considering Now
Feb-05-25 06:00AM - Tech investors are aggressively buying the dip: Morning Brief
Oct-10-24 11:04AM - Markets have digested Nvidia's 'sustainability': Portfolio mgr.
Sep-08-23 10:02AM - Resilient US economy, oil's inflation impact, and China vs. Apple: Top takeaways of the week

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-06-24T12:34:00Z - 4 Best Inverse/Leveraged ETF Areas of Last Week
B2 - 2024-02-15T01:29:04Z - Jim Cramer Dismisses Bearish Market 'Scares' After Wednesday's Rebound: 'No Need To Pretend That The Sky Is Falling'
B3 - 2023-10-24T12:00:00Z - 5 Best-Performing ETFs of Last Week
B4 - 2023-08-24T20:23:00Z - Bullish on Nvidia? This single-stock ETF could offer 1.5 times leverage on the chip maker stock — but be careful what you wish for

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for GraniteShares ETF Trust (NVD).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

NVD_OUT_3 [2025-04-16 13:59:34 -0400] 868 Bytes | 223 tokens | Cum: 977 tkns (12.21% of 8k)
==========================================================================

Showing B4 (chunk 1 of 1): B4:
**Bullish on Nvidia? This single-stock ETF could offer 1.5 times leverage on the chip maker stock — but be careful what you wish for**Date: Unknown DateSource: Unknown SourceURL: https://www.marketwatch.com/story/bullish-on-nvidia-this-single-stock-etf-could-offer-1-5-times-leverage-on-the-chip-maker-stock-but-be-careful-what-you-wish-for-c9966f8fWhile Nvidia’s blow out earnings reignite the artificial-intelligence trade in the U.S. stock market, some risk-seeking investors are looking for ways to gain more exposure to the clear leader in the chip manufacturing industry.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NVD_OUT_5 [2025-04-16 13:59:35 -0400] 380 Bytes | 87 tokens | Cum: 1066 tkns (13.33% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

NVD_OUT_7 [2025-04-16 13:59:35 -0400] 336 Bytes | 98 tokens | Cum: 1166 tkns (14.57% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
Document A1 not found. Only 0 articles available.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NVD_OUT_9 [2025-04-16 13:59:41 -0400] 1052 Bytes | 373 tokens | Cum: 1541 tkns (19.26% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2009-11-16 10-Q PART I FIN INFO

ITEM 1. FIN STATEMENTS

NOVADEL PHARMA INC.

COND BAL SHEETS

AS OF SEPTEMBER 30, 2009 (UNAUDITED) & DECEMBER 31, 2008

ASSETS

September 30, 2009 (unaudited)

December 31, 2008 (Note 2)

Curr Assets:

Cash and cash ...

S2 - 2009-08-12 10-Q PART I FIN INFO

ITEM 1. FIN STATEMENTS

NOVADEL PHARMA INC.

COND BAL SHEETS

AS OF JUNE 30, 2009 (UNAUDITED) & DECEMBER 31, 2008

ASSETS

June 30, 2009

(unaudited)

December 31, 2008

(Note 2)

Curr Assets:

Cash and cash equivalent...

S3 - 2009-05-15 10-Q PART I FIN INFO

ITEM 1. FIN STATEMENTS

NOVADEL PHARMA INC.

COND BAL SHEETS

AS OF MARCH 31, 2009 (UNAUDITED) & DECEMBER 31, 2008

ASSETS

March 31, 2009

(unaudited)

December 31, 2008

(Note 2)

Curr Assets:

Cash and cash equivale...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

NVD_OUT_11 [2025-04-16 13:59:41 -0400] 1181 Bytes | 373 tokens | Cum: 1916 tkns (23.95% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
PART I FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

NOVADEL PHARMA INC.

CONDENSED BALANCE SHEETS

AS OF SEPTEMBER 30, 2009 (UNAUDITED) AND DECEMBER 31, 2008

ASSETS

September 30, 2009 (unaudited)

December 31, 2008 (Note 2)

Current Assets:

Cash and cash equivalents

$ 327,000 $ 4,328,000 Assets held-for-sale

299,000 299,000 Deferred financing costs, net of accumulated amortization of $238,000 and $213,000, respectively

25,000 Prepaid expenses and other current assets

553,000 958,000 Total Current Assets

1,179,000 5,610,000 Property and equipment, net

1,060,000 1,447,000 Other assets

32,000 259,000 TOTAL ASSETS

$ 2,271,000 $ 7,316,000 LIABILITIES AND STOCKHOLDERS DEFICIENCY

Current Liabilities:

Secured convertible notes payable, net of unamortized debt discount of zero and $403,000, respectively

$ 3,000,000 $ 3,597,000 Notes pay

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NVD_OUT_13 [2025-04-16 13:59:42 -0400] 1181 Bytes | 354 tokens | Cum: 2272 tkns (28.40% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): able

159,000 Accounts payable

924,000 654,000 Accrued expenses and other current liabilities

1,019,000 924,000 Current portion of deferred revenue

266,000 266,000 Current portion of capital lease obligations

34,000 122,000 Total Current Liabilities

5,402,000 5,563,000 Non-current portion of deferred revenue

4,269,000 4,468,000 Non-current portion of capital lease obligations

7,000 26,000 Total Liabilities

9,678,000 10,057,000 COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS DEFICIENCY

Preferred stock, $.001 par value:

Authorized 1,000,000 shares, none issued

Common stock, $.001 par value:

Authorized 200,000,000, issued 63,606,374 and 60,692,260 shares at September 30, 2009 and December 31, 2008, respectively

64,000 60,000 Additional paid-in capital

72,925,000 72,034,000 Accumulated deficit

(80,390,000 ) (74,829,000 ) Less: treasury stock, at c

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NVD_OUT_15 [2025-04-16 13:59:43 -0400] 1181 Bytes | 388 tokens | Cum: 2662 tkns (33.27% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): ost, 3,012 shares

(6,000 ) (6,000 ) Total Stockholders Deficiency

(7,407,000 ) (2,741,000 ) TOTAL LIABILITIES AND STOCKHOLDERS DEFICIENCY

$ 2,271,000 $ 7,316,000

See accompanying notes to condensed financial statements.

NOVADEL PHARMA INC.

CONDENSED STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS AND NINE MONTHS ENDED

SEPTEMBER 30, 2009 AND SEPTEMBER 30, 2008

(UNAUDITED)

Three Months Ended

Nine Months Ended

September 30, 2009

September 30, 2008

September 30, 2009

September 30, 2008

License Fees and Milestone Fees Earned

$ 223,000 $ 104,000 $ 356,000 $ 258,000 Research and Development Expenses

530,000 705,000 1,980,000 3,151,000 Consulting, Selling, General and Administrative Expenses

973,000 1,164,000 3,167,000 3,473,000 Loss on Assets Held-for-Sale

9,000 351,000 Total Expenses

1,503,000 1,878,000 5,147,000 6,975,000 Loss From Operat

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NVD_OUT_17 [2025-04-16 13:59:46 -0400] 1181 Bytes | 388 tokens | Cum: 3052 tkns (38.15% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): ions

(1,280,000 ) (1,774,000 ) (4,791,000 ) (6,717,000 ) Other Income

301,000 Interest Expense

(81,000 ) (750,000 ) (717,000 ) (1,044,000 ) Interest Income

21,000 6,000 84,000 Net Loss

$ (1,361,000 ) $ (2,503,000 ) $ (5,201,000 ) $ (7,677,000 ) Basic and Diluted Loss Per Common Share

$ (0.02 ) $ (0.04 ) $ (0.09 ) $ (0.13 ) Weighted Average Number of Common Shares Used in Computation of Basic and Diluted Loss Per Common Share

61,385,722 59,592,000 60,458,548 59,592,000

See accompanying notes to condensed financial statements.

NOVADEL PHARMA INC.

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS DEFICIENCY

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2009

(UNAUDITED)

Common Stock

Shares

Amount

Additional Paid-In Capital

Accumulated

Deficit

Treasury Stock

Total Stockholders Deficiency

BALANCE, December 31, 2008

60,692,260 $ 60,000 $ 72,034

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NVD_OUT_19 [2025-04-16 13:59:47 -0400] 1181 Bytes | 396 tokens | Cum: 3450 tkns (43.12% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): ,000 $ (74,829,000 ) $ (6,000 ) $ (2,741,000 ) Share-based compensation expense

251,000 251,000 Cumulative effect for the adoption of ASC 815-40-15 relating to outstanding warrants indexed to the entitys own stock

(360,000 ) (360,000 ) Restricted stock cancelled

(575,000 ) Cashless exercise of warrants

489,114 1,000 (1,000 ) Issuance of Common Stock

3,000,000 3,000 641,000 644,000 Net loss

(5,201,000 ) (5,201,000 ) BALANCE, September 30, 2009

63,606,374 $ 64,000 $ 72,925,000 $ (80,390,000 ) $ (6,000 ) $ (7,407,000 )

See accompanying notes to condensed financial statements.

NOVADEL PHARMA INC.

CONDENSED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2009 AND SEPTEMBER 30, 2008

(UNAUDITED)

Nine Months Ended

September 30, 2009

September 30, 2008

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss

$ (5,201,000 ) $ (7,677,000 ) Adj

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NVD_OUT_21 [2025-04-16 13:59:49 -0400] 790 Bytes | 207 tokens | Cum: 3659 tkns (45.74% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): ustments to reconcile net loss to net cash used in operating activities:

Share-based compensation expense

251,000 600,000 Expiration of warrants

(360,000 ) Amortization of debt discount and deferred financing fees

428,000 968,000 Depreciation and amortization

287,000 397,000 Loss on assets held for sale

351,000 Loss on disposition of fixed assets

59,000 Changes in operating assets and liabilities:

Prepaid expenses and other current assets

405,000 127,000 Other assets

22...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NVD_OUT_23 [2025-04-16 13:59:57 -0400] 3957 Bytes | 937 tokens | Cum: 4598 tkns (57.48% of 8k)
==========================================================================

This is our set of metrics for GraniteShares ETF Trust.
Please analyze the numbers.

+-------------------+-----------------+----------------------+-------------------------+
| Volume: 3,870,233 | ATR (14): 4.67 | Perf Week: 18.79% | Market Cap: |
+-------------------+-----------------+----------------------+-------------------------+
| Avg Volume: 4.76M | SMA20: -3.25% | Perf Month: 1.95% | Shs Outstand: |
+-------------------+-----------------+----------------------+-------------------------+
| Rel Volume: 1.22 | SMA50: 3.94% | Perf Quarter: 11.18% | Option/Short: Yes / Yes |
+-------------------+-----------------+----------------------+-------------------------+
| RSI (14): 49.49 | SMA200: -16.70% | Index: - | Beta: -2.86 |
+-------------------+-----------------+----------------------+-------------------------+

The next section covers any insider trading by GraniteShares ETF Trust officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 32
Average Volume: 4256055.87
30-Day High: 44.37
30-Day Low: 26.58
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of GraniteShares ETF Trust (NVD).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about GraniteShares ETF Trust.

2) MARKET_SCORE[]
This conversation was initiated because NVD is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for NVD.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, NVD could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect NVD to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of GraniteShares ETF Trust.

11) ETHICAL_RATING[]
Rate GraniteShares ETF Trust’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of GraniteShares ETF Trust.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

NVD_IN_25 [2025-04-16 13:59:58 -0400] 126 Bytes | 29 tokens | Cum: 4836 tkns (60.45% of 8k)
==========================================================================

====================================
[2025-04-16 13:59:58] # Analysis Completed
Elapsed Time: 25.65 seconds